Abstract
The time delay between drug plasma concentrations and effect has been modeled most commonly by the effect compartment approach, assuming first-order monoexponential equilibrium kinetics between plasma and effect site. So far this assumption has not been rigorously probed. The purpose of the present investigation was to model the delay between amobarbital plasma concentrations and EEG effect using a new approach based on system analysis principles. This approach models the equilibrium between plasma and effect site without assuming a specific kinetic structure. Assuming linear distribution kinetics between plasma and effect site, the relationship between the two variables may be described by a convolution type of linear operation, involving a conductance function ϕ(t),which is approximated by a sum of exponentials. Six male Wistarderived rats received an iv infusion of amobarbital at a rate of 10mg/kg per min until isoelectric periods of 5sec or longer appeared on the EEG. Frequent arterial blood samples were obtained and EEG was continuously quantified using aperiodic analysis. The amplitudes in the 2.5–30Hz frequency band were used as EEG effect measure. The delay between plasma concentrations and EEG effect was best modeled by a biexponential conductance function. The use of a biexponential conductance function resulted in a significant further reduction (41 ± 10%)in hysteresis when compared to a monoexponential function, indicating that the assumption of simple first-order monoexponential equilibration kinetics is inadequate. The use of a biexponential conductance function also resulted in a significantly different shape of the effect site concenration- EEG effect relationship and hence the estimated pharmacodynamic parameters, when compared with a monoexponential function. This relationship showed a biphasic behavior, with EEG effects being maximal at amobarbital concentrations of 29.6± 1.3mg/L. At 80.2±2.0mg/L the EEG effect was reduced 50%below baseline values. A comparison was made with the equilibration between amobarbital plasma and cerebrospinal fluid (CSF) concentrations. Six male Wistarderived rats received an iv infusion of amobarbital, 10mg per min for 15min. Arterial blood and CSF samples were taken simultaneously at regular intervals. The equilibration between plasma and CSF concentrations was best fitted by a monoexponential conductance function. Significant differences in equilibration profiles of CSF and effect site with the plasma site were observed. To reach 50%equilibrium the effect site requires 2.5±0.3min and the CSF 3.5±0.2min, to reach 95%the values were, respectively, 90± 27and 15± 1min. This suggests that CSF is kinetically distinguishable from the effect site.
Similar content being viewed by others
References
N. H. G. Holford and L. B. Sheiner. Pharmacokinetic and pharmacodynamic modeling in vivo.CRC Crit. Rev. Bioeng. 5:273–322 (1981).
D. R. Stanski, R. J. Hudson, T. D. Homer, L. J. Saidman, and E. Meathe. Pharmacodynamic modeling of thiopental anesthesia.J. Pharmacokin. Biopharm. 12:223–240 (1984).
J. S. Scott, K. V. Ponganis, and D. R. Stanski. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanyl.Anesthesiology 62:234–241 (1985).
G. Segré. Kinetics of interaction between drugs and biological systems.Farmaco 23:907–918 (1968).
C. J. Hull, H. B. H. Van Beem, K. McLeod, A. Sibbald, and M. J. Watson. A pharmacodynamic model for pancuronium.Br. J. Anaesth. 50:1113–1123 (1978).
L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine.Clin. Pharmacol. Ther. 25:358–371 (1979).
E. Fuseau and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model.Clin. Pharmacol. Ther. 35:733–741 (1984).
J. D. Unadkat, F. Bartha, and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.Clin. Pharmacol. Ther. 40:86–93 (1986).
D. Verotta, S. L. Beal, and L. B. Sheiner. Semiparametric approach to pharmacokineticpharmacodynamic data.Am. J. Physiol. 256:R1005-R1010 (1989).
P. Veng-Pedersen, J. W. Mandema, and M. Danhof. A system approach to pharmacodynamics III: An algorithm and computer program ‘COLAPS’ for pharmacodynamic modeling.J. Pharm. Sci. 80:488–495 (1991).
J. W. Mandema and M. Danhof. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis.J. Pharmacokin. Biopharm. 18:459–481 (1990).
J. B. M. M. van Bree, A. V. Baljet, A. van Geyt, A. G. de Boer, M. Danhof, and D. D. Breimer. The unit impulse response procedure for the pharmacokinetic evaluation of drug entry into the central nervous system.J. Pharmacokin. Biopharm. 17:441–462 (1989).
P. Veng-Pedersen and W. R. Gillespie. A system approach to pharmacodynamics I: theoretical framework.J. Pharm. Sci. 77:39–47 (1988).
H. G. Boxenbaum, S. Riegelman, and R. M. Elashoff. Statistical estimations in pharmacokinetics.J. Pharmacokin. Biopharm. 2:123–148 (1974).
M. Gibaldi and D. Perrier. Noncompartmental analysis based on statistical moment theory. InPharmacokinetics, 2nd ed. Marcel Dekker, New York, 1982, pp. 409–424.
P. Veng-Pedersen, J. W. Mandema, and M. Danhof. Biophase equilibration times.J. Pharm. Sci. 80:881–886 (1991).
W. F. Ebling, M. Danhof, and D. R. Stanski. Pharmacodynamic characterization of the electroencephalographic effects of thiopental in rats.J. Pharmacokin. Biopharm. 19:123–143 (1991).
P. Veng-Pedersen. Linear and nonlinear systems approaches in pharmacokinetics: how much do they have to offer? II. The response mapping operator (RMO) approach.J. Pharmacokin. Biopharm. 16:543–571 (1988).
P. O. Maitre, M. Bührer, S. L. Shafer, and D. R. Stanski. Estimating the rate of thiopental blood-brain equilibration using pseudo steady-state serum concentrations.J. Pharmacokin. Biopharm. 18:175–187 (1990).
R. J. Hudson, D. R. Stanski, L. J. Saidman, and E. Meathe. A model for studying depth of aneshesia and acute tolerance to thiopental.Anesthesiology 59:301–308 (1983).
J. Dingemanse, D. Thomassen, B. H. Mentink, and M. Danhof. Strategy to assess the role of (inter)active metabolites in pharmacodynamic studies in vivo: a model study with heptabarbital.J. Pharm. Pharmacol. 40:552–557 (1988).
H. H. Frey and M. P. Magnussen. Contribution to the metabolism of amobarbital and the pharmacological significance of its main metabolite, 5-ethyl-5-(3-hydroxyisopentyl) barbituric acid.Arzneim. Forsch. (Drug Res.)16:612–615 (1966).
M. Danhof and G. Levy. Kinetics of drug action in disease states I. Effects of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex.J. Pharmacol. Exp. Ther. 229:44–50 (1984).
S. Toon and M. Rowland. Structure-pharmacokinetic relationships among the barbiturates in the rat.J. Pharmacol. Exp. Ther. 225:752–763 (1983).
M. Danhof, M. Hisaoka, and G. Levy. Kinetics of drug action in disease states. II. Effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss of righting reflex.J. Pharmacol. Exp. Ther. 230:627–631 (1984).
J. Dingemanse, M. Polhuijs, and M. Danhof. Altered pharmacokinetic-pharmacodynamic relationship of heptabarbital in experimental renal failure in rats.J. Pharmacol. Exp. Ther. 241:371–376 (1988).
Author information
Authors and Affiliations
Additional information
Supported by MEDIGON grant 900-521-106.
Rights and permissions
About this article
Cite this article
Mandema, J.W., Veng-Pedersen, P. & Danhof, M. Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions. Journal of Pharmacokinetics and Biopharmaceutics 19, 617–634 (1991). https://doi.org/10.1007/BF01080870
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01080870